Oppenheimer downgraded Carlyle Group from Outperform to Perform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/14/2025 | $56.00 | Hold → Buy | TD Cowen |
| 3/19/2025 | Outperform → Perform | Oppenheimer | |
| 1/3/2025 | $60.00 | Peer Perform → Outperform | Wolfe Research |
| 9/12/2024 | $42.00 | Equal Weight | Wells Fargo |
| 8/27/2024 | $55.00 | Buy | Redburn Atlantic |
| 8/6/2024 | $46.00 → $44.00 | Overweight → Neutral | JP Morgan |
| 1/19/2024 | $40.00 → $41.00 | Buy → Neutral | Citigroup |
| 1/4/2024 | $42.00 | Market Perform | TD Cowen |
Transaction positions company for accelerated growth through improved capital structure and simplified governance LINDON, Utah and NEW YORK, June 4, 2025 /PRNewswire/ -- Trucordia today announced it will receive a $1.3 billion strategic investment from global investment firm Carlyle's Global Credit platform. The transaction will reduce Trucordia's leverage and simplify its governance structure by repurchasing units from existing minority investors. The transaction, which is expected to close this month and values Trucordia at $5.7 billion, provides the company with long-term
New management, led by David Meek, is committed to rapidly scaling access to lifechanging gene therapies Significant capital commitment from Carlyle and SK Capital will enable bluebird to grow and accelerate patient access bluebird will focus on expanding manufacturing capacity and improving the treatment experience for patients and providers bluebird bio (NASDAQ:BLUE) ("bluebird"), a pioneer in gene therapies for severe genetic diseases, today announced the completion of its sale to funds managed by global investment firms Carlyle (NASDAQ:CG) and SK Capital Partners, LP ("SK Capital"). With the closing of the transaction, bluebird's common stock has ceased trading and will no longer
All conditions of the Offer have been satisfied and the parties expect to consummate the acquisition on June 2, 2025 Carlyle (NASDAQ:CG) ("Carlyle"), SK Capital Partners, LP ("SK Capital") and Beacon Parent Holdings, L.P. ("Parent") today announced that the tender offer commenced on March 7, 2025 to acquire all of the outstanding common stock of bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird") for either (x) $3.00 per share in cash and a contingent value right per share, entitling the holder to a payment of $6.84 in cash per contingent value right ("CVR") if bluebird's current product portfolio achieves $600 million in net sales in any trailing 12-month period prior to or ending on December
8-K - Carlyle Group Inc. (0001527166) (Filer)
SCHEDULE 13G/A - Carlyle Group Inc. (0001527166) (Subject)
13F-HR - Carlyle Group Inc. (0001527166) (Filer)